AstraZeneca to invest $2B in newly issued Summit Therapeutics equity, plus clinical collaboration on ivonescimab

AstraZeneca has agreed to invest $2 billion in newly issued Summit Therapeutics equity to accelerate development of ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, in combination with antibody drug conjugates across tumour types. The two companies also entered a clinical collaboration agreement to evaluate sonesitatug vedotin with ivonescimab.

Detected & updated continuously · Source: Nebula